Rounds
Precision BioSciences, Inc.
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS platform to treat rare genetic conditions.
Precision BioSciences, Inc. is a biotech & life sciences company. It has raised $125 million in disclosed funding. Its latest round was an Undisclosed stage of $125 million in November 2026.
Overview
Precision BioSciences utilizes its proprietary ARCUS genome-editing technology to engineer medicines for various conditions, including rare genetic diseases. The ARCUS platform employs sequence-specific enzymes, known as nucleases, capable of inserting, removing, or repairing DNA within living cells and tissues [0]. The company focuses on the development of therapeutic candidates designed to address hard-to-treat conditions [0]. According to OSH records, the company has raised $125 million in total funding [registry]. The organization maintains a focus on building a diverse workforce and actively recruits new personnel to support its mission [1, 3].
gene-editingtherapeuticsbiotechnologyARCUSgenomics
Funding
Total disclosed: $125M across 1 round. Computed only from sourced rounds.
| Date | Company | Amount | Stage | Lead | Other investors | Sector | Sources |
|---|---|---|---|---|---|---|---|
| $125M | — | — | — | Biotech & Life Sciences | 1 |
Nov 5
In the news
Questions and answers
What does Precision BioSciences, Inc. do?
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS platform to treat rare genetic conditions.
How much has Precision BioSciences, Inc. raised?
Precision BioSciences, Inc. has raised $125 million in disclosed funding across 1 round tracked by OSH.
Sources
- 1.Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | FinancialContent — financialcontent.com
- 2.Precision BioSciences, Inc. · Official
- 3.Precision BioSciences, Inc. · Official
- 4.Precision BioSciences, Inc. · Official
- 5.Precision BioSciences, Inc. · Official